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Nodules on the trunk and the arm of an 8-year-old boyCase report
An 8-year-old boy presented with three painless nodules on the
abdomen, back, and left arm for the duration of 1 year (Figure 1).
The skin examination showed three 10 mm 6 mm skin-colored,
well-circumscribed, dome-shaped nodules on the abdomen, lower
back, and left antecubital fossa. The patient had strabismus and left
ptosis for 2 years, and maculopathy was noted for 1 month. He had
no hearing loss or tinnitus. Tracing back his medical history, he had
relative attention deﬁcit, poor memory, lethargy, and coordination
disorder, especially in ﬁne movement for 3 years. There was no
family history. Skin biopsy was done over abdomen (Figure 1A).
Microscopic ﬁnding showed multiple encapsulated cellular
nodules consisting of spindle cell with Verocay bodies, and plexi-
form schwannoma was impressed. Meanwhile, gene analysis was
performed. A heterozygous nonsense mutation (1219C>T, Q407X)
was detected in Exon 12 by direct DNA sequencing (Figure 2A).
The father and mother showed normal sequence (Figure 2B).
Auditory brainstem response showed normal brainstem audi-
tory evoked potential. The initial brain magnetic resonance
imaging (MRI) showed a tumor within left internal acoustic canal
favoring vestibular schwannoma and a right cerebellopontine
angle tumor favoring trigeminal schwannoma (Figure 3).Figure 1 Skin-colored, well-circumscribed, dome-shaped nodules about 10 mm 6 mm on the (A) abdomen and (B) lower back of the 8-year-old boy.
Figure 2 (A) Automated DNA sequencing of NF2 gene reveals a single nucleotide
nonsense mutation (1219C>T, Q407X) in Exon 12. (B) Normal sequence from control
and parents.
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Figure 3 Bilateral vestibular schwannomas (arrows) and trigeminal schwannoma
(arrowhead) in axial T1-weighted contrast-enhanced brain magnetic resonance
imaging.
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De novo mutation of neuroﬁbromatosis type II (NF2).
Discussion
Cyberknife stereotactic radiotherapy with 2100 cGy in three frac-
tions targeting the former and 2250 cGy in ﬁve fractions targeting
the latter were done in order. The two tumors seemed to be
stationary for about 2 years. However, new enhancing tumors on
the brain MRI was noted over left oculomotor and facial nerves,
and right vestibular and lower cranial nerves afterward. Further
follow-up was suggested.
NF2 (OMIM101000) is an inherited autosomal dominant,multiple
neoplasia syndrome characterized by tumors of the eighth cranial
nerve (usuallybilateral),meningiomasof thebrain, andschwannomas
of thedorsal roots of the spinal cord.NF2 is causedbymutations inNF2
tumor suppressor gene, which contains 17 exons on chromosome
22q12. Merlin (moesin-ezrin-radixin-like protein) or schwannomin,
which is encoded by the Exon 1–15 and 17 of NF2 gene and has 595
amino acid residues, contains three domains in order: a trilobed
amino-terminal FERM (four-point-one, ezrin, radixin, moesin)
domain, an a-helical domain, and a carboxy-terminal domain. The
FERM domain connects to carboxy-terminal domain when the
serine-518 on the latter is phosphorylated, and the coiling of merlin
at this active stage enables the tumor suppression activity.1 Mutation
ofNF2gene results in theuniquespectrumof tumor formation, suchas
schwannomas and other lesions in the nervous system, eyes, and skin.
According to the study of Selvanathan et al,2 there are correla-
tions between the genotypes and phenotypes in NF2. Patients
with nonsense or frameshift mutations are associated with severer
presentation. They are younger at diagnosis; become symptomatic
earlier; more likely to have meningiomas, spinal tumors, and non-
vestibular cranial nerve tumors; and have more cutaneous lesions.2
Splice site mutations are related to both mild and severe disease
and may be milder if occurring in the 3’ half of the gene. Missense
mutations are usually mild, often causing the mildest form of NF2.3
Besides, patients with truncating mutations were signiﬁcantly
more likely to develop symptoms before 20 years of age anddevelop at least two symptomatic central nervous system tumors
in addition to vestibular schwannoma before 30 years of age.4
NF2 was ﬁrst described in a deaf patient with tumors in the
skull, dura mater, and brain in 1822. It was considered to be related
to the other types of neuroﬁbromatoses, such as neuroﬁbromatosis
type 1 (NF1) and schwannomatosis.1 However, not until 1987 did
the localization of NF2 and NF1 on chromosome 22 and 17q11
respectively separate them as different entities. In clinical manifes-
tation, schwannomas are common in NF2, whereas neuroﬁbromas
are common in NF1. Schwannomatosis was further discriminated
from NF2 by its deﬁnition as multiple schwannomas without
vestibular schwannomas that are diagnostic of NF2 and its muta-
tion of INI1 (SMARCB1) gene on chromosome 22q11.3
The clinical diagnosis is made, according to Manchester criteria,
by fulﬁlling either one of the four conditions, including (1) bilateral
vestibular schwannomas; (2) ﬁrst-degree relative with NF2 and
either having unilateral vestibular schwannoma or any two of the
following: meningioma, glioma, neuroﬁbroma, schwannoma,
posterior subcapsular lenticular opacities; (3) unilateral vestibular
schwannoma and any two of the following: meningioma, glioma,
neuroﬁbroma, schwannoma, and posterior subcapsular lenticular
opacities; (4) multiple meningiomas and unilateral vestibular
schwannoma or any two of the following: glioma, neuroﬁbroma,
schwannoma, and cataract.5
Evaluations after initial diagnosis must include: brain MRI,
hearing evaluation (auditory brainstem response), ophthalmologic
evaluation, and cutaneous examination.3 The treatment mainly
focuses on the manifestations of each system. Surgery and stereo-
tactic radiotherapy are the choices for vestibular schwannoma.Acknowledgments
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